---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-26-000042"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2026-05-18T11:17:15+00:00"
generated_at: "2026-05-18T11:20:46.530715+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific enters $2B accelerated share repurchase, expects $0.02 EPS accretion in FY2026

## Summary
- ASR with JPMorgan for $2B; receives ~30.4M shares upfront at $52.68 (80% of repurchase price).
- Final settlement expected by June 30, 2026; total shares based on VWAP during term less discount.
- After completion, $3B remains under $5B share repurchase authorization.
- Expected net impact to adjusted EPS in FY2026 is $0.02 accretive to prior guidance (Apr 22, 2026).

## SEC filing metadata
- accession: 0000885725-26-000042
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2026-05-18T11:17:15+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572526000042/0000885725-26-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572526000042/bsx-20260518.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-26-000042
- JSON: https://secwatch.observer/filing/0000885725-26-000042.json
- Plain text: https://secwatch.observer/filing/0000885725-26-000042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.